Диссертация (1174280), страница 20
Текст из файла (страница 20)
– 1993. – Т. 16. – №. 7. – С. 716-719.65. Huelsbrink, R. Lambert–Eaton myasthenic syndrome–Diagnosis, pathogenesisand therapy / R. Huelsbrink, S. Hashemolhosseini.//Clinical Neurophysiology. –2014. – Т. 125. – №. 12. – С. 2328-2336.66. Ha, J. C. Myasthenia gravis and related disorders: Pathology and molecularpathogenesis / J.C. Ha, D.P. Richman.//Biochimica et Biophysica Acta (BBA)Molecular Basis of Disease. – 2015. – Т. 1852. – №. 4. – С. 651-657.67. Hajela, R. K. Lambert–Eaton syndrome antibodies target multiple subunits ofvoltage‐gated Ca2+ channels / R.K. Hajela, K.M.
Huntoon, W.D.Atchison.//Muscle & nerve. – 2015. – Т. 51. – №. 2. – С. 176-184.68. Harms, L. Long-term disease history, clinical symptoms, health status, andhealthcare utilization in patients suffering from Lambert Eaton myasthenicsyndrome: results of a patient interview survey in Germany / L. Harms, J.P. Sieb,A.E. Williams et al.//Journal of medical economics. – 2012.
– Т. 15. – №. 3. – С.521-530.69. Harvey, A.M. The electromyogram in myasthenia gravis / A.M. Harvey, R.L.Masland.// Bull Johns Hopkins Hosp. 1941 – № 1 (69).70. Hawley, R. J. The carcinomatous neuromyopathy of oat cell lung cancer / R.J.Hawley, M.H. Cohen, N. Saini et al.//Annals of Neurology: Official Journal of theAmerican Neurological Association and the Child Neurology Society. – 1980. – Т.7. – №. 1.
– С. 65-72.71. Heathfield, K. W. G. Peripheral neuropathy and myopathy associated withbronchogenic carcinoma / K.W.G. Heathfield, J.R.B. Williams.//Brain. – 1954. –Т. 77. – №. 1. – С. 122-137.72. Huijbers, M. G. Antibodies to active zone protein ERC1 in Lambert–Eatonmyasthenic syndrome / M.G. Huijbers, A.F. Lipka, M. Potman et al.//Humanimmunology. – 2013. – Т. 74. – №. 7. – С. 849-851.73.
Huijbers, M. G. MuSK IgG4 autoantibodies cause myasthenia gravis byinhibiting binding between MuSK and Lrp4 /M.G. Huijbers, W. Zhang, R.134Klooster et al.//Proceedings of the National Academy of Sciences. – 2013. – Т.110. – №. 51. – С. 20783-20788.74. Iwasa, K. Recombinant calcium channel is recognized by Lambert–Eatonmyasthenic syndrome antibodies / K. Iwasa, M. Takamori, K. Komai etal.//Neurology. – 2000. – Т. 54. – №.
3. – С. 757-757.75. Jolly, F. Ueber myasthenia gravis pseudoparalytica / F. Jolly.//Berl Klin Wschr.– 1895. – Т. 32. – С. 1-7.76. Juel, V.C. Myasthenia gravis / V.C. Juel, J.M. Massey.// Orphanet journal ofrare diseases. 2007. – (2). – C. 44.77. Juel, V.C. The Lambert–Eaton myasthenic syndrome / V.C. Juel, D.B.Sanders. – Myasthenia gravis and myasthenic disorders– 2nd edn. OxfordUniversity Press, Oxford. 2012.
– C. 156–169.78. Kanzato, N. Lambert–Eaton myasthenic syndrome with ophthalmoparesis andpseudoblepharospasm / N. Kanzato, M. Motomura, M. Suehara et al. //Muscle &Nerve: Official Journal of the American Association of ElectrodiagnosticMedicine. – 1999. – Т. 22. – №. 12. – С. 1727-1730.79. Katyal, N.
Pure ocular weakness as the initial manifestation of Lambert–Eatonmyasthenic syndrome / N. Katyal, R. Govindarajan.//Cureus. – 2017. – Т. 9. – №.12.80. Kazarian, M. Small-cell lung cancer-associated autoantibodies: potentialapplications to cancer diagnosis, early detection, and therapy / M. Kazarian, I. A.Laird-Offringa.//Molecular Cancer. – 2011. – Т. 10. – №. 1. – С. 33.81.
Kesner, V. G. Lambert-Eaton myasthenic syndrome / V.G. Kesner, S.J. Oh,M.M. Dimachkie et al.//Neurologic clinics. – 2018. – Т. 36. – №. 2. – С. 379-394.82. Key, R. G. Anti‐Yo mediated paraneoplastic cerebellar degeneration in thecontext of breast cancer: a case report and literature review / R.G. Key, J.C.
Root.//Psycho‐Oncology. – 2013. – Т. 22. – №. 9. – С. 2152-2155.83. Kimura, J. Electrodiagnosis in diseases of nerve and muscle: principles andpractice. / J. Kimura. – Oxford university press, 2013.84. Krarup, C. Electrical and mechanical responses in the platysma and in theadductor pollicis muscle: in normal subjects / C. Krarup. //Journal of Neurology,Neurosurgery & Psychiatry.
– 1977. – Т. 40. – №. 3. – С. 234-240.13585. Krarup, C. Evoked responses of the elbow flexors in control subjects and inmyopathy patients / C. Krarup, S.H. Horowitz. //Muscle & Nerve: Official Journalof the American Association of Electrodiagnostic Medicine. – 1979. – Т. 2. – №. 6.– С. 465-477.86. Kuzanne, M. Paraneoplastic syndromes and constitutional symptoms inprediction of metastatic behavior of small cell carcinoma of the lung / M.
Kuzanne,G.M. Hutchins, G. william Moore.//The American journal of medicine. – 1984. –Т. 77. – №. 5. – С. 851-857.87. Lambert, E. H. Defect of neuromuscular conduction assoicated with malignantneoplasma / E.H. Lambert. //Am J Physiol. – 1956. – Т. 187. – С. 612-613.88. Lambert, E. H. Myastenic syndrome occasionally associated with bronchialneoplasm: Neurophysiologic studies / E.H. Lambert. //Myasthenia gravis. – 1961.– С. 362-410.89. Lambert, E. H. Quantal components of end‐plate potentials in the myasthenicsyndrome / E.H. Lambert, D. Elmqvist.//Annals of the New York Academy ofSciences.
– 1971. – Т. 183. – №. 1. – С. 183-199.90. Lang, B. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome /B. Lang, D. Wray, J. Newsom-Davis et al.//The Lancet. – 1981. – Т. 318. – №.8240. – С. 224-226.91. Lang, B. Pathogenic autoantibodies in the Lambert‐Eaton myasthenicsyndrome / B. Lang, A. Pinto, F. Giovannini et al.//Annals of the New YorkAcademy of Sciences.
– 2003. – Т. 998. – №. 1. – С. 187-195.92. Lang, B. Autoantibodies to ion channels at the neuromuscular junction / B.Lang, A. Vincent.//Autoimmunity reviews. – 2003. – Т. 2. – №. 2. – С. 94-100.93. Lemal, R. Large granular lymphocytic leukemia associated with Lambert–Eaton Myasthenic Syndrome: A case report / R. Lemal, C. Chaleteix, P. Minard etal.//Leukemia research reports.
– 2013. – Т. 2. – №. 1. – С. 32-33.94. Lennon, V. A. Calcium-channel antibodies in the Lambert–Eaton syndromeand other paraneoplastic syndromes / V.A. Lennon, T.J. Kryzer, G.E. Griesmann etal.//New England Journal of Medicine. – 1995. – Т. 332. – №. 22. – С. 1467-1475.95. Lennon, V. A. Serologic profile of myasthenia gravis and distinction from theLambert-Eaton myasthenic syndrome /V.A. Lennon.//Neurology. – 1997. – Т.
48.– №. Suppl 5. – С. 23S-27S.13696. Lorenzoni, P. J. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: abrief review of 10 cases / P.J. Lorenzoni, R.H. Scola, C.S. Kay et al.//Arquivos deneuro-psiquiatria. – 2010. – Т. 68. – №. 6. – С. 849-854.97. Low, P. A. Composite autonomic scoring scale for laboratory quantification ofgeneralized autonomic failure / P.A. Low.//Mayo Clinic Proceedings. – Elsevier,1993. – Т. 68. – №.
8. – С. 748-752.98. Low, P. A. Autonomic symptoms and diabetic neuropathy: a population-basedstudy / P.A. Low, L.M. Benrud-Larson, D.M. Sletten et al.//Diabetes care. – 2004.– Т. 27. – №. 12. – С. 2942-2947.99. Luigetti, M. Low rate repetitive nerve stimulation in Lambert-Eatonmyasthenic syndrome: peculiar characteristics of decremental pattern from asingle-centre experience / M. Luigetti, A.
Modoni, M.M. Lo.//Clinicalneurophysiology: official journal of the International Federation of ClinicalNeurophysiology. – 2013. – Т. 124. – №. 4. – С. 825.100. Maddison, P. Favourable prognosis in Lambert-Eaton myasthenic syndromeand small-cell lung carcinoma / P. Maddison, J. Newsom-Davis, K.R. Mills etal.//The Lancet. – 1999. – Т. 353. – №.
9147. – С. 117-118.101. Maddison, P. Long term outcome in Lambert-Eaton myasthenic syndromewithout lung cancer / P. Maddison, B. Lang, K. Mills et al.//Journal of Neurology,Neurosurgery & Psychiatry. – 2001. – Т. 70. – №. 2. – С. 212-217.102. Maddison, P. Paraneoplastic neurological autoimmunity and survival insmall-cell lung cancer / P.
Maddison, B. Lang. //Journal of neuroimmunology. –2008. – Т. 201. – С. 159-162.103. Mantegazza, R. The European LEMS Registry: baseline demographics andtreatment approaches / R. Mantegazza, A. Meisel, J.P. Sieb et al.//Neurology andtherapy. – 2015. – Т. 4. – №. 2. – С. 105-124.104. Mantegazza, R. Myasthenia gravis: from autoantibodies to therapy / R.Mantegazza, P. Bernasconi, P.
Cavalcante.//Current opinion in neurology. – 2018.– Т. 31. – №. 5. – С. 517-525.105. Martin-Moutot, N. Synaptotagmin: a Lambert-Eaton myasthenic syndromeantigen that associates with presynaptic calcium channels / N. Martin-Moutot, O.El Far, C. Leveque et al.//Journal of Physiology-Paris. – 1993. – Т. 87. – №. 1. –С. 37-41.137106. Martin-Moutot, N. Distinct evolution of calcium channel antibody types inLambert–Eaton myasthenic syndrome / N. Martin-Moutot, L. De Haro, M.Seagar.//Journal of neuroimmunology.
– 2008. – Т. 197. – №. 1. – С. 47-53.107. Matsumoto, R. Myasthenia gravis with electrophysiological features ofLambert-Eaton myasthenic syndrome: usefulness of serum autoantibodies assayand neuromuscular junction biopsy /R. Matsumoto, M. Motomura, T. Yoshimuraet al.//Rinsho shinkeigaku= Clinical neurology. – 1999. – Т. 39.
– №. 5. – С. 531537.108. McEvoy, K. M. Diagnosis and treatment of Lambert-Eaton myasthenicsyndrome /K.M. McEvoy.//Neurologic clinics. – 1994. – Т. 12. – №. 2. – С. 387400.109. Milanez, F. M. Lung adenocarcinoma, dermatomyositis, and Lambert-Eatonmyasthenic syndrome: a rare combination / F.M. Milanez, C. Pereira, P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
